SHANGHAI, March 2, 2025 /PRNewswire/ — CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation (BTD) to satricabtagene autoleucel (“satri-cel”,… Continue reading CARsgen’s Claudin18.2 CAR-T Therapy Satri-cel Granted Breakthrough Therapy Designation by the NMPA
Category: Automotive
CHARLES LECLERC AND CHIVAS REGAL HIT THE RIGHT NOTE IN NEW GLOBAL PARTNERSHIP
Chivas Regal welcomes Charles Leclerc as Global Brand Ambassador with an exclusive pop-up piano bar ahead of the first Grand Prix of the season, with an appearance from the self-taught pianist. LONDON, March 2, 2025 /PRNewswire/ — Luxury Scotch whisky, Chivas Regal, has announced leading Formula 1 driver Charles Leclerc as its Global Brand Ambassador… Continue reading CHARLES LECLERC AND CHIVAS REGAL HIT THE RIGHT NOTE IN NEW GLOBAL PARTNERSHIP
Charles Leclerc y Chivas Regal dan en el blanco en una nueva alianza global
Chivas Regal da la bienvenida a Charles Leclerc como Embajador Global de la Marca con un exclusivo piano bar emergente antes del primer Gran Premio de la temporada, con la aparición del pianista autodidacta. LONDRES, 3 de marzo de 2025 /PRNewswire/ — El whisky escocés de lujo Chivas Regal ha anunciado que el destacado piloto… Continue reading Charles Leclerc y Chivas Regal dan en el blanco en una nueva alianza global
CHARLES LECLERC AND CHIVAS REGAL HIT THE RIGHT NOTE IN NEW GLOBAL PARTNERSHIP
Chivas Regal welcomes Charles Leclerc as Global Brand Ambassador with an exclusive pop-up piano bar ahead of the first Grand Prix of the season, with an appearance from the self-taught pianist. LONDON, March 2, 2025 /PRNewswire/ — Luxury Scotch whisky, Chivas Regal, has announced leading Formula 1 driver Charles Leclerc as its Global Brand Ambassador… Continue reading CHARLES LECLERC AND CHIVAS REGAL HIT THE RIGHT NOTE IN NEW GLOBAL PARTNERSHIP
CHARLES LECLERC ET CHIVAS REGAL : LA BONNE NOTE POUR UN NOUVEAU PARTENARIAT MONDIAL
Chivas Regal accueille Charles Leclerc en tant qu’ambassadeur mondial de la marque avec un piano-bar pop-up exclusif avant le premier Grand Prix de la saison, avec une apparition du pianiste autodidacte. LONDRES, 2 mars 2025 /PRNewswire/ — Le whisky écossais de luxe Chivas Regal a annoncé que le pilote de Formule 1 Charles Leclerc serait… Continue reading CHARLES LECLERC ET CHIVAS REGAL : LA BONNE NOTE POUR UN NOUVEAU PARTENARIAT MONDIAL
CHARLES LECLERC UND CHIVAS REGAL TREFFEN MIT NEUER GLOBALER PARTNERSCHAFT DEN RICHTIGEN TON
Chivas Regal begrüßt Charles Leclerc als globalen Markenbotschafter mit einer exklusiven Pop-up-Piano-Bar im Vorfeld des ersten Grand Prix der Saison, in der der autodidaktische Pianist auftritt. LONDON, 2. März 2025 /PRNewswire/ — Der schottische Luxus-Whisky Chivas Regal hat den führenden Formel-1-Fahrer Charles Leclerc als seinen globalen Markenbotschafter im Rahmen einer mehrjährigen Partnerschaft bekannt gegeben und… Continue reading CHARLES LECLERC UND CHIVAS REGAL TREFFEN MIT NEUER GLOBALER PARTNERSCHAFT DEN RICHTIGEN TON
Pulnovo Medical Announces Closing of Nearly $100 Million Series C Financing
SHANGHAI, March 2, 2025 /PRNewswire/ — Pulnovo Medical, a globally recognized pioneer in medical devices for pulmonary hypertension (PH) and heart failure (HF), has announced the closing of nearly $100 million Series C financing. This round was co-led by Qiming Venture Partners and existing shareholder Lilly Asia Ventures, with existing investors OrbiMed and Gaorong Capital… Continue reading Pulnovo Medical Announces Closing of Nearly $100 Million Series C Financing
Head-to-Head Against Pembrolizumab: Innovent Announces First Patient Dosed in the First Pivotal Study of IBI363 (PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Melanoma
SAN FRANCISCO and SUZHOU, China, March 2, 2025 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology, and other major diseases, announced that the first patient has been dosed in its registrational study evaluating IBI363, a… Continue reading Head-to-Head Against Pembrolizumab: Innovent Announces First Patient Dosed in the First Pivotal Study of IBI363 (PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Melanoma
FTAI Deadline: FTAI Investors with Losses in Excess of $100K Have Opportunity to Lead FTAI Aviation Ltd. Securities Fraud Lawsuit
NEW YORK, March 2, 2025 /PRNewswire/ — Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of FTAI Aviation Ltd. (NASDAQ: FTAI) between July 23, 2024, and January 15, 2025, both dates inclusive (the “Class Period”), of the important March 18, 2025 lead plaintiff deadline. So what: If you purchased FTAI… Continue reading FTAI Deadline: FTAI Investors with Losses in Excess of $100K Have Opportunity to Lead FTAI Aviation Ltd. Securities Fraud Lawsuit
ATKR Investors Have Opportunity to Lead Atkore Inc. Securities Fraud Lawsuit
NEW YORK, March 2, 2025 /PRNewswire/ — Why: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action on behalf of purchasers of common stock of Atkore Inc. (NYSE: ATKR) between February 1, 2024 and February 3, 2025, both dates inclusive (the “Class Period”). If you wish to serve as… Continue reading ATKR Investors Have Opportunity to Lead Atkore Inc. Securities Fraud Lawsuit